Indegene profit and loss

Latest FY26
Revenue
₹3,511cr+23.6% on FY25
EBITDA
₹619cr+15.9% on FY25
Net profit
₹401cr−1.4% on FY25
EPS
₹16.72−2.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
4,1313,5112,8392,590
74.272.010776.3
4,2053,5832,9472,666
Expenses
2,5412,1981,8151,652
25.119.322.049.4
17212680.276.1
907694490433
3,6453,0372,4072,210
683619534505
511493454429
Profit
560545539456
−20.3−20.30.02.4
540525539459
180176149126
−51.6−52.4−16.5−3.6
129124133122
411401407337
411401407337
10713925.67.9
518541432345
411401407345
Per share
₹17.12₹16.72₹17.15₹15.19
₹17.01₹16.62₹17.02₹15.07
Other comprehensive income — detail
10713925.6—
2.84.1−2.10.0
0.71.0−0.5—
10313527.27.9
−1.8−1.70.0—
406541432—
Per share — as-filed variants
₹17.12₹16.72₹17.15₹15.19
₹17.01₹16.62₹17.02₹15.07
Adjusted (ex-exceptional items) — derived
560545539456
−20.3−20.30.02.4
427417407335
₹17.76₹17.37₹17.15₹15.11
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹593.45

Indegene Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,272 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue from Operations2,589.62,839.33,510.54,130.9
Other Income76.3107.272.074.2
Total Income2,665.92,946.53,582.54,205.1
Expenses
+ Employee Benefit Expense1,651.61,815.22,197.72,541.2
+ Finance Costs49.422.019.325.1
+ Depreciation & Amortisation76.180.2126.4171.9
+ Other Expenses432.6489.8693.8906.7
Total Expenses2,209.72,407.23,037.23,644.9
EBITDA505.4534.3619.0683.0
EBIT429.3454.1492.6511.1
Profit
PBT before Exceptional Items456.2539.3545.3560.2
+ Exceptional Items2.40.0-20.3-20.3
Pretax Income458.6539.3525.0539.9
+ Current Tax125.5149.1176.3180.4
+ Deferred Tax-3.6-16.5-52.4-51.6
Tax Expense121.9132.6123.9128.8
Net Income336.7406.7401.1411.1
+ Net Income — Continuing Ops336.7406.7401.1411.1
+ Other Comprehensive Income7.925.6139.4107.1
Total Comprehensive Income344.6432.3540.5518.2
Net Income to Common344.6406.7401.1411.1
Per Share
Basic EPS15.1917.1516.7217.12
Diluted EPS15.0717.0216.6217.01
Other Comprehensive Income — detail
+ Other Comprehensive Income—25.6139.4107.1
+ Items NOT to be Reclassified to P&L0.0-2.14.12.8
+ Tax on Items NOT to be Reclassified—-0.51.00.7
+ Items to be Reclassified to P&L7.927.2134.6103.2
+ Tax on Items to be Reclassified—0.0-1.7-1.8
Comprehensive Income — Owners of Parent—432.3540.5405.9
Per Share — as-filed variants
Basic EPS — Continuing Operations15.1917.1516.7217.12
Diluted EPS — Continuing Operations15.0717.0216.6217.01
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)456.2539.3545.3560.2
− Exceptional Items (reconciliation)2.40.0-20.3-20.3
Net Income Adj (tax-effected)334.9406.7416.6426.6
EPS Adj15.1117.1517.3717.76
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital44.447.948.148.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.